About
Oragenics, Inc. is a development-stage company dedicated to developing drugs, therapies and vaccines through intra-nasal delivery. We continue to strengthen our focus and build our expertise around intranasal drug delivery platforms through new strategic partnerships. On December 28, 2023, we closed our asset purchase agreement with Odyssey Health, Inc. to acquire all of their neurology assets related to treating mild traumatic brain injury, also known as concussion and for treating Niemann Pick Disease Type C (ONP-002 and ONP-001). Also included in the assets acquired was their proprietary powder formulation and its nasal delivery device, which Oragenics believes to be novel.
Most recently Oragenics research and development projects were focused on infection diseases including coronaviruses and multidrug-resistant organisms. Oragenics is excited to add a nasal delivery drug product to their portfolio focused on developing a treatment for brain related illness and injury. Following the acquisition of ONP-002 and ONP-001 Oragenics will be focusing efforts in this new important area of treating concussion.
Concussion is an unmet medical need, there is an estimated 69M concussion annually reported worldwide. Other neurological disorders including Alzheimer’s Disease, Parkingson’s Disease, and Chronic Traumatic Encephalopathy (CTE) have been linked to concussions.
Mission
Our mission is focused on developing life enhancing medical products that have a clinical advantage and serve an unmet need.
History
In October of 2023, we announced the signing of a definitive agreement with Odyssey Health, Inc. to acquire assets related to their proprietary neurological drug therapies, including their proprietary formulation and nasal delivery system. The assets include drug candidates for treating mild traumatic brain injury, also known as concussion, and for treating Niemann Pick Disease Type C.
Members of our scientific team discovered that a certain bacterial strain, Streptococcus mutans, produces MU1140, a molecule belonging to the novel class of antibiotics known as lantibiotics. Lantibiotics, such as MU1140, are highly modified peptide antibiotics made by a small group of Gram-positive bacterial species. Over 60 lantibiotics have been discovered, to date. We believe lantibiotics are generally recognized by the scientific community to be potent antibiotic agents.
In May of 2020, we acquired Noachis Terra, Inc. and as a result, we are now focused on the development and commercialization of a vaccine product candidate to provide long lasting immunity from the novel Severe Acute Respiratory Syndrome coronavirus (“SARS-CoV-2”), which causes the coronavirus disease 2019. We are a party to a worldwide, nonexclusive intellectual property and biological materials license agreement with the National Institute of Allergy and Infectious Diseases, an institute within the National Institutes of Health (NIH), relating to certain research, patent applications and biological materials involving pre-fusion stabilized coronavirus spike proteins and their use in the development and commercialization of a vaccine to provide specific, long-lasting immunity from SARS-CoV-2.
In March of 2021, we entered into a material transfer agreement with Biodextris Inc. for the use of three intranasal mucosal adjuvants in our Terra CoV-2 vaccine against COVID-19. Adjuvants are added to vaccines to enhance their immunogenicity.
In July of 2021, we entered into a licensing agreement with the National Research Council of Canada (NRC) that will enable us to pursue the rapid development of next-generation vaccines against the SARS-CoV-2 virus and its variants. The National Research Council of Canada (NRC) technologies, in combination with the National Institutes of Health (NIH) elements found in our NT-CoV-2 candidate, provide us with a platform that can generate cell lines for high-yield production of spike protein antigens for existing and emerging variants of concern. This platform should allow production of cell lines within six to eight weeks of spike gene sequence availability, compared with six to nine months for traditional production of such cell lines. The National Research Council of Canada (NRC) technologies, developed with support from the National Research Council of Canada (NRC) Pandemic Response Challenge Program, are expected to expedite the evaluation of SARS-CoV-2 antigen candidates in preclinical and clinical studies.
Developing Treatments to Combat Resistant Infectious Diseases
We possess and develop technologies and product candidates that originate from the discoveries of our scientific team.